CRISPR ‘Drama’ Plays Out at the USPTO


Robert Underwood said “it is very unlikely that the US Patent and Trademark Office will say that there is no interference,” in a hearing to determine the true inventor of the CRISPR gene-editing technology. He added that the PTO judges must “be able to determine whether the technology in dispute itself is at all patentable. The longer the case goes on, the bigger are the chances that the board may come to this conclusion,” which he suggested may make a settlement agreement the best solution in the case.